Research Consortia Need Funding, But FDA Is More “Honest Broker”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants data standards in place so the increasingly popular clinical research collaborations can continue growing, but a researcher states that government also could make funding available to sustain the consortia.
You may also be interested in...
Cancer Progress Requires Integrating Data And Therapeutics – AACR Report
As genomic analysis produces ever-increasing amounts of data on cancer biology, continued progress in oncology will require advances in managing and analyzing data and new approaches to clinical trial design to increase efficiency and address development of treatment resistance to molecularly targeted therapies, the American Association for Cancer Research asserts in its annual Cancer Progress report.
Cancer Progress Requires Integrating Data And Therapeutics – AACR Report
As genomic analysis produces ever-increasing amounts of data on cancer biology, continued progress in oncology will require advances in managing and analyzing data and new approaches to clinical trial design to increase efficiency and address development of treatment resistance to molecularly targeted therapies, the American Association for Cancer Research asserts in its annual Cancer Progress report.
FDA Master Protocol In Metastatic Breast Cancer Likely In The Works
Oct. 21 public workshop cosponsored by prominent oncology groups will discuss international genomically driven trial to test multiple agents in metastatic breast cancer.